Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 3/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13517937 | 0.81 | MAOA (0.45) | CHRNB4CHRNA3MAOAMAOBADRA1D | |
| SCHEMBL13727045 | 0.81 | MAOA (0.45) | CHRNB4CHRNA3MAOAMAOBADRA1D | |
| SCHEMBL13517093 | 0.81 | MAOA (0.45) | CHRNB4CHRNA3MAOAMAOBADRA1D | |
| SCHEMBL8199655 | 0.79 | CHRNB4 (0.50) | CHRNB4CHRNA3ACHEDRD2OPRD1 | |
| SCHEMBL8204830 | 0.79 | CA2 (0.50) | CHRNB4CHRNA3ADRA1DADRA1AADRA1B | |
| SCHEMBL13998649 | 0.76 | ADRA1D (0.50) | MAOAMAOBADRA1DADRA1AADRA1B | |
| SCHEMBL6002699 | 0.76 | CYP11B1 (0.56) | — | |
| SCHEMBL8116022 | 0.75 | CHRNB4 (0.47) | CHRNB4CHRNA3 | |
| SCHEMBL9093837 | 0.75 | CHRNB4 (0.47) | CHRNB4CHRNA3 | |
| SCHEMBL17818432 | 0.73 | CHRNB4 (0.41) | CHRNB4CHRNA3ACHEMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465737-B2 | Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl -6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives | SANOFI-AVENTIS (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20070225300-A1 | HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL -6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2007-09-27 | — | — | US | disclosed |
| WO-2000058301-A1 | N-[2-(4-AMINOPHYL)ETHYL]-2,3-DIHYDRO-1,4-BENZODIOXINE-2-METHANAMINE, PRODUCTION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225300-A1 | HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL -6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES | CDK5, CDK5R1, PSEN2 | CHRNB4 896/4885CHRNA3 484/4885ACHE 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.